Latest Administration News

FINEOS Corporation Holdings PLC reported a solid €39 million cash balance for Q2 2026 despite a 23% drop in client receipts due to timing. The company locked in a significant 10-year deal with OneAmerica Financial and maintained its FY26 revenue guidance between €147m and €152m.

Syrah Resources moderated graphite output amid subdued ex-China demand, raised US$72 million to support ramp-up, and advanced Vidalia anode material towards commercial sales in H2 2026.

Adheris Health’s revenue and profit fell sharply in Q4 FY26 due to the previous challenging pharma budget cycle, but the company achieved cashflow break-even and ended the period with $9.5 million in net cash.

Tissue Repair Limited (ASX: TRP) has applied to delist from the ASX, citing limited liquidity and high listing costs. The company plans a shareholder vote and a $1 million off-market buy-back at a premium to recent prices.

Monvia Limited, an Australian SaaS provider for life insurers, is seeking to raise $17.5 million via an IPO on the ASX. The funds will support redemption of preference shares and fuel growth in existing and new markets.

Adslot Technologies, the troubled subsidiary of Adslot Ltd, has gained creditor backing to execute a Deed of Company Arrangement, aiming to satisfy non-related creditors while maintaining group control of its technology platform.

Alpha HPA Limited progresses construction of its flagship Stage 2 facility on schedule and budget, while product demand surges across semiconductor and battery sectors, with forecasts exceeding 50,000 tonnes per annum.

Praemium’s total Funds Under Administration surged 21% to $77.9 billion in FY26, driven by strong platform net inflows and robust growth in non-custodial portfolio administration.

88 Energy has boosted its South Prudhoe oil prospects by 35%, securing key assets and advancing drilling plans for Q1 2027 while reducing capital risk in Namibia.

Paladin Energy completes Langer Heinrich Mine ramp-up, delivering strong FY2026 results and advancing its Canadian PLS Project with a new uranium discovery. FY2027 guidance forecasts stable production and costs amid ongoing regulatory progress.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.